SBIR/STTR Research Award
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs
Award amount
$224,737Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ELYSIUM THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- CQ2LJLATAKH9
- Solicitation number
- DA14-013
- Topic code
- NIDA
Research abstract
DESCRIPTION: Elysium has discovered a novel molecular deactivation (XpiRx or expiring pill ) technology that is designed to effectively curb the widespread abuse and diversion of unused prescription opioid drugs. Using Elysium's technology, opioid drug products will safely, and irreversibly lose their potency over a specified time window beyond the prescribed use period, rendering them devoid of opioid agonist effects, and, therefore, completely abuse-resistant. Our XpiRx technology enables: (i) effectivepain relief during the prescribed use period; (ii) abuse-resistance via non-oral routes; (iii) oral abuse-deterrence beyond the prescribed use period; and (iv) oral overdose protection beyond the programmed expiration date. According to President Obama,Prescription drug abuse is America's fastest-growing drug problem, and one largely fed by an unlikely source - Americans' medicine cabinets. Over 70% of abusers obtain unused prescription opioids from their friends and family. Current opioid pills lose on
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods
- Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids
- Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs
- Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance
- Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
6 SBIR/STTR records share this UEI (2014–2018). Reported award amounts total $6,722,094. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services